CoLucid Pharmaceuticals
12
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
25%
3 trials in Phase 3/4
100%
12 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
Role: collaborator
A Study of Lasmiditan on the Heart in Healthy Participants
Role: collaborator
Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration
Role: collaborator
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
Role: collaborator
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
Role: collaborator
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Role: collaborator
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
Role: collaborator
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
Role: collaborator
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Role: collaborator
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
Role: collaborator
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Role: collaborator
Food-Effect Study in Healthy Participants
Role: collaborator
All 12 trials loaded